(0.04%) 5 189.93 points
(0.50%) 39 077 points
(-0.15%) 16 308 points
(1.03%) $79.19
(-1.18%) $2.18
(-0.32%) $2 316.70
(0.04%) $27.56
(-0.09%) $987.55
(0.13%) $0.931
(0.07%) $10.91
(0.12%) $0.800
(0.19%) $91.62
-1.29% $ 0.581
Live Chart Being Loaded With Signals
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases...
Stats | |
---|---|
Volumen de hoy | 83 889.00 |
Volumen promedio | 52 473.00 |
Capitalización de mercado | 25.48M |
EPS | $0 ( 2023-11-13 ) |
Last Dividend | $0.580 ( 2023-06-21 ) |
Next Dividend | $0 ( N/A ) |
P/E | -0.564 |
ATR14 | $0.0160 (2.75%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2023-03-23 | Klassen Preston | Sell | 842 211 | Common Stock |
2023-03-23 | Klassen Preston | Sell | 842 211 | Stock Option (right to buy) |
2023-01-26 | York Michael | Sell | 107 054 | Common Stock |
2023-01-26 | Klassen Preston | Sell | 380 605 | Common Stock |
2022-12-21 | Leonard Braden Michael | Buy | 120 099 | Common Stock |
INSIDER POWER |
---|
-17.12 |
Last 97 transactions |
Buy: 12 877 287 | Sell: 12 262 808 |
Volumen Correlación
Metacrine, Inc. Correlación
10 Correlaciones Más Positivas | |
---|---|
LMRK | 0.865 |
KNBE | 0.855 |
AFBI | 0.834 |
OCAX | 0.833 |
IMRA | 0.83 |
AGFS | 0.83 |
QADA | 0.827 |
XOMAO | 0.824 |
EYEG | 0.821 |
STTK | 0.817 |
10 Correlaciones Más Negativas | |
---|---|
GNUS | -0.872 |
AGIL | -0.858 |
CNEY | -0.858 |
UTRS | -0.857 |
TANH | -0.855 |
MOTS | -0.851 |
BLUE | -0.849 |
PCSA | -0.844 |
ADN | -0.829 |
BJDX | -0.827 |
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
Metacrine, Inc. Correlación - Moneda/Commodity
Metacrine, Inc. Finanzas
Annual | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.40 |
FY | 2021 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-2.40 |
FY | 2020 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.436 |
FY | 2019 |
Ingresos: | $0.00 |
Beneficio Bruto: | $0.00 (0.00 %) |
EPS: | $-1.520 |
Financial Reports:
No articles found.
Metacrine, Inc. Dividends
(Q1/23) | (Q2/23) | (Q3/23) | (Q4/23) | (Q1/24) | (Q2/24) | (Q3/24) | (Q4/24) |
$0 (N/A) |
$0.580 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
$0 (N/A) |
Very Unsafe
High risk of being cut
Unsafe
Heightened risk of being cut
Borderline
Moderate risk of being cut
Safe
Unlikely to be cut
Very Safe
Very unlikely to be cut
First Dividend | $0.580 | 2023-06-21 |
Last Dividend | $0.580 | 2023-06-21 |
Next Dividend | $0 | N/A |
Payout Date | 0000-00-00 | |
Next Payout Date | N/A | |
# dividends | 1 | -- |
Total Paid Out | $0.580 | -- |
Avg. Dividend % Per Year | 43.27% | -- |
Score | 4.01 | -- |
Div. Sustainability Score | 0 | |
Div.Growth Potential Score | 0 | |
Div. Directional Score | 0 | -- |
Year | Amount | Yield |
---|---|---|
2023 | $0.580 | 129.80% |
2024 | $0 | 0.00% |
Unable to generate commentary due to missing data.
Symbol | Title | Last dividend | Frequency | Years Dividend | Yearly Dividend | Score |
---|---|---|---|---|---|---|
PSEC | Dividend Royal | 2023-12-26 | Monthly | 21 | 7.04% | 8.50 |
SLVO | Dividend Royal | 2023-11-20 | Monthly | 12 | 10.77% | 8.50 |
QYLD | Dividend Royal | 2023-11-20 | Monthly | 11 | 7.50% | 8.50 |
GAIN | Dividend Royal | 2023-12-04 | Monthly | 20 | 8.19% | 8.50 |
GLDI | Dividend Royal | 2023-11-20 | Monthly | 12 | 7.15% | 8.50 |
OXLC | Dividend Royal | 2023-12-14 | Monthly | 14 | 10.00% | 8.50 |
OXSQ | Dividend Royal | 2023-12-14 | Monthly | 21 | 9.10% | 8.50 |
HRZN | Dividend King | 2023-12-18 | Monthly | 15 | 6.60% | 8.45 |
USOI | Dividend Royal | 2023-11-20 | Monthly | 8 | 16.70% | 8.28 |
PFLT | Dividend King | 2023-11-15 | Monthly | 14 | 6.50% | 8.27 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
netProfitMarginTTM | 0 | 1.500 | 0 | 0 | [0 - 0.5] |
returnOnAssetsTTM | -0.766 | 1.200 | -10.00 | -10.00 | [0 - 0.3] |
returnOnEquityTTM | -0.835 | 1.500 | -10.00 | -10.00 | [0.1 - 1] |
payoutRatioTTM | 0 | -1.000 | 0 | 0 | [0 - 1] |
currentRatioTTM | 10.15 | 0.800 | 10.00 | 8.00 | [1 - 3] |
quickRatioTTM | 13.40 | 0.800 | 10.00 | 8.00 | [0.8 - 2.5] |
cashRatioTTM | 9.85 | 1.500 | 10.00 | 10.00 | [0.2 - 2] |
debtRatioTTM | 0.177 | -1.500 | 7.06 | -10.00 | [0 - 0.6] |
interestCoverageTTM | -50.81 | 1.000 | -10.00 | -10.00 | [3 - 30] |
operatingCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -0.747 | [0 - 30] |
freeCashFlowPerShareTTM | -1.120 | 2.00 | -0.560 | -1.120 | [0 - 20] |
debtEquityRatioTTM | 0.246 | -1.500 | 9.01 | -10.00 | [0 - 2.5] |
grossProfitMarginTTM | 0 | 1.000 | -3.33 | -3.33 | [0.2 - 0.8] |
operatingProfitMarginTTM | 0 | 1.000 | -2.00 | -2.00 | [0.1 - 0.6] |
cashFlowToDebtRatioTTM | -3.34 | 1.000 | -10.00 | -10.00 | [0.2 - 2] |
assetTurnoverTTM | 0 | 0.800 | -3.33 | -2.67 | [0.5 - 2] |
Total Score | -0.578 |
Ratio | Actual Value | Weight | Normalized Value | Score | Range |
---|---|---|---|---|---|
peRatioTTM | -0.400 | 1.000 | -0.141 | 0 | [1 - 100] |
returnOnEquityTTM | -0.835 | 2.50 | -6.68 | -10.00 | [0.1 - 1.5] |
freeCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -1.120 | [0 - 30] |
dividendYielPercentageTTM | 99.76 | 1.500 | 10.00 | 0 | [0 - 0.4] |
operatingCashFlowPerShareTTM | -1.120 | 2.00 | -0.373 | -0.747 | [0 - 30] |
payoutRatioTTM | 0 | 1.500 | 0 | 0 | [0 - 1] |
pegRatioTTM | 0 | 1.500 | -3.33 | 0 | [0.5 - 2] |
operatingCashFlowSalesRatioTTM | 0 | 1.000 | -2.50 | 0 | [0.1 - 0.5] |
Total Score | -0.413 |
Metacrine, Inc.
Metacrine, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing therapies for patients with gastrointestinal diseases. It is developing MET642, which has completed Phase I clinical trial for the treatment of ulcerative colitis. Metacrine, Inc. was incorporated in 2014 and is headquartered in San Diego, California.
Acerca de Señales en Vivo
Las señales en vivo presentadas en esta página ayudan a determinar cuándo COMPRAR o VENDER NA. Las señales tienen un retraso de más de 1 minuto; como todas las señales del mercado, existe la posibilidad de error o errores.
Las señales de trading en vivo no son definitivas y getagraph.com no asume ninguna responsabilidad por cualquier acción tomada sobre estas señales, como se describe en los Términos de Uso. Las señales se basan en una amplia gama de indicadores de análisis técnico